One way to enhance the therapeutic potential of antibodies is to combine, or “conjugate,” them to small molecule drugs, which brings together the compound’s ability to target a specific antigen and the potential benefit of a combination drug. Another way to enhance the therapeutic potential of antibodies is to use a technology that allows the generation of a dual-specific antibody to target two antigens (also called a dual-variable domain antibody).
Learn more about our pioneering oncology research and development
Turanli-Yildiz B, Alkim C, Cakar ZP. Protein Engineering Methods and Applications. Protein Engineering. 2012;ISBN 9789535100379:33-58. Source
Discovery of small molecule cancer drugs: Successes, challenges and opportunities, Mol Oncol, Aprio 2012;6(2):155-176.
Alberts, B., Johnson, A., Lewis, J., Morgan, D., Raff, M., Roberts, K., & Walter, P. (2015). Cell death, Molecular biology of the cell (6th ed.). (pp. 1021-1034). New York, NY: Garland Science.
National Cancer Institute FactSheet, Biological Therapies for Cancer: http://www.cancer.gov/cancertopics/factsheet/Therapy/biological , accessed April 29, 2014.
Sassoon I, Blanc V. Antibody-drug conjugate (ADC) clinical pipeline: a review. Methods Mol Biol. 2013;1045:1-27.
Eigenbrot, C. & Fuh, G. Two-in-One antibodies with dual action Fabs. Current Opinion in Chemical Biology. 2013; 17: 400-405.